Summary

Overview
Global Superficial Punctate Keratitis Market reached US$ XX million in 2022 and is expected to reach US$ XX million by 2030, growing at a CAGR of XX% during the forecast period 2023-2030.
Superficial punctate keratitis is an eye disorder caused by the death of small groups of cells on the surface of the cornea. It is usually caused by infection by bacteria, viruses, strong spillage of chemicals in the eye, prolonged usage of contact lenses, and others.
In superficial punctate keratitis, the eyes are usually painful, watery, sensitive to bright light, and bloodshot, and vision may be slightly blurred. Also, there will be a burning, gritty feeling or a feeling as if a foreign object is trapped in the eye.
Market Dynamics: Drivers & Restraints
Increase in research and developmental activities
Factors such as an increase in the demand for healthcare, technological advancements, increasing pharma production, and the rising prevalence of contagious diseases are expected to drive the market growth. The incidence of the disease is rising due to the poor sanitary conditions in the developing and underdeveloped nations.
The increase in the research and developmental activities in developing new drugs for treating superficial punctate keratitis is expected to drive the market growth in the forecast period. The increase in the number of drug options helps the individuals suffering from the disease which in return increases the market growth.
Restraint
Stringent regulations associated with the approvals
The stringent regulations, high costs of research and development, and patent expirations. The lack of reimbursement policies for the treatment is expected to hinder market growth.
Segment Analysis
The global superficial punctate keratitis market is segmented based on drugs, route of administration, distribution channel and region.
Topical Natamycin (5%) segment accounted for 38.4% of the market share
Natamycin is expected to hold a significant position in the market share due to its efficiency in treating the disease. Topical natamycin is the first-line therapy for superficial mycosis. Natamycin is a tetraene polyene that has been regarded as the most important agent in the management of fungal keratitis. In superficial punctate keratitis, the eyes are usually painful, watery, sensitive to bright light, and bloodshot, and vision may be slightly blurred.
Natamycin is considered a primary choice for filamentous fungal infections but is characterized by poor corneal penetration due to its high molecular weight and poor solubility and is mostly effective in cases of superficial keratitis. Thus, the above factors are expected to hold the segment in the dominant position.
Geographical Analysis
North America is expected to hold a significant position in the global superficial punctate keratitis market share
North American region accounted for the largest market share due to the increased prevalence of the disease, and increased health campaigns in the region to bring awareness among individuals regarding the spread of the disease and the presence of major players in introducing the medications that prevent the disease.
The increase in the number of individuals using contact lenses in the region is also expected to increase the prevalence of the disease. This is the most common problem associated with contact lens wearing and may occur as a result of dry eye. It is then usually seen in the lower half of the cornea as little scattered fluorescein staining dots. Thus, the above factors are driving the market growth in the region.
COVID-19 Impact Analysis
COVID-19 has impacted the superficial punctate keratitis market negatively. The shift in the company's interest and increased demand for COVID-19 vaccines and medicines has impacted the market negatively.
Market Segmentation
By Drugs
● Topical Natamycin (5%)
● Amphotericin B
o Bacitracin
o Gentamicin
● Voriconazole
● Short-acting Cycloplegic Drug
o Cyclopentolate 1% Drop
● LOTEMAX
By Route of Administration
● Oral
● Topical
● Intravenous
By Distribution Channel
● Hospital Pharmacies
● Retail Pharmacies
● Online Pharmacies
By Region
● North America
o U.S.
o Canada
o Mexico
● Europe
o Germany
o UK
o France
o Italy
o Spain
o Rest of Europe
● South America
o Brazil
o Argentina
o Rest of South America
● Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
● Middle East and Africa
Competitive Landscape
The leading companies with a significant market share include Harrow Inc., Thermo Fisher Scientific Inc., Matinas BioPharma Hldgs, Glenmark Pharmaceuticals Limited, Cayman Chemical Company, Dr. Reddy’s Laboratories Ltd., Gilead Sciences Inc., Xellia ApS, Merck KGaA, Pfizer Inc. among others.
Why Purchase the Report?
● To visualize the global superficial punctate keratitis market segmentation based on equipment type, treatment type, end-users and region as well as understand key commercial assets and players.
● Identify commercial opportunities by analyzing trends and co-development.
● Excel data sheet with numerous data points of superficial punctate keratitis market-level with all segments.
● PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
● Product mapping available as excel consisting of key products of all the major players.
The global superficial punctate keratitis market report would provide approximately 61 tables, 68 figures, and 183 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

ページTOPに戻る

Table of Contents

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Drugs
3.2. Snippet by Route of Administration
3.3. Snippet by Distribution Channel
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increase in research and developmental activities
4.1.1.2. XX
4.1.2. Restraints
4.1.2.1. Stringent regulations associated with the approvals
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Russia-Ukraine War Impact Analysis
5.6. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Equipment Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
7.1.2. Market Attractiveness Index, By Drugs
7.2. Topical Natamycin (5%) *
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Amphotericin B
7.3.1. Bacitracin
7.3.2. Gentamicin
7.4. Voriconazole
7.5. Short-acting Cycloplegic Drug
7.5.1. Cyclopentolate 1% Drop
7.6. LOTEMAX
8. By Route of Administration
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
8.1.2. Market Attractiveness Index, By Route of Administration
8.2. Oral*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Topical
8.4. Intravenous
9. By Distribution Channel
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.2. Market Attractiveness Index, By Distribution Channel
9.3. Hospitals *
9.3.1. Introduction
9.3.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.4. Specialty Clinics
9.5. Ambulatory Surgical Centers
9.6. Others
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. UK
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.5.1. China
10.5.5.2. India
10.5.5.3. Japan
10.5.5.4. Australia
10.5.5.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. Harrow Inc *
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. Thermo Fisher Scientific Inc
12.3. Matinas BioPharma Hldgs
12.4. Glenmark Pharmaceuticals Limited
12.5. Cayman Chemical Company
12.6. Dr. Reddy’s Laboratories Ltd.
12.7. Gilead Sciences Inc.
12.8. Xellia ApS
12.9. Merck KGaA
12.10. Pfizer Inc.
LIST NOT EXHAUSTIVE
13. Appendix
13.1. About Us and Services
13.2. Contact Us